EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Associations Between Gene Variants of Lipid‐Lowering Drug Targets and Adverse Outcomes After Ischemic Stroke

Lulu Sun, Qilu Zhang iD, Mengyao Shi, Yang Liu iD, Zhengbao Zhu iD, Jing Zhang iD, Hao Peng iD, Aili Wang, Jing Chen iD, Tan Xu iD, Yonghong Zhang iD, Jiang He iD

Journal of the American Heart Association · 2024

DOI: 10.1161/jaha.124.036544 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Lulu Sun und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-communic…. Hauptthemen laut MEDLINE: Cholesterol Ester Transfer Proteins, Hydroxymethylglutaryl CoA Reductases, Ischemic Stroke, Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background The association of lipid‐lowering drug targets and their gene variants with cardiovascular diseases has been previously clarified. However, the relationship between gene variants of lipid‐lowering drug targets and the adverse prognosis of ischemic stroke patients remains unclear. Methods and Results Multiple single‐nucleotide polymorphisms associated with 6 lipid‐lowering drug targets were genotyped for patients with ischemic stroke. The primary outcome was death or major disability within 2 years after ischemic stroke. Genetic risk score was constructed from significant single‐nucleotide polymorphisms identified via additive models, which was calculated by multiplying the number of risk alleles at each locus by the corresponding beta coefficient and then summing the products. The rs2006760‐C of the HMGCR , rs11206510‐T of PCSK9 , and rs1864163‐G and rs9929488‐G of CETP were associated with increased odds of adverse outcomes within 2 years after ischemic stroke. Each additional risk allele was associated with higher odds of adverse outcomes. Genetic risk score was positively associated with the odds of primary outcome (odds ratio [OR], 1.48 [95% CI, 1.15–1.90]; P trend = 0.001), major disability (OR, 1.56 [95% CI, 1.16–2.08]; P trend = 0.002), death (hazard ratio [HR], 1.58 [95% CI, 1.12–2.25]; P trend = 0.011), and the composite outcome of death or cardiovascular events (HR, 1.41 [95% CI, 1.08–1.85]; P trend = 0.010) when 2 extreme quartiles were compared. Conclusions rs2006760‐C of HMGCR , rs11206510‐T of PCSK9 , and rs1864163‐G and rs9929488‐G of CETP were associated with increased odds of adverse outcomes within 2 years after ischemic stroke. Furthermore, higher GRS was positively related to the odds of poor outcomes in patients with ischemic stroke. Registration: URL: https://www.clinicaltrials.gov ; Identifier: NCT01840072.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholesterol Ester Transfer ProteinsHydroxymethylglutaryl CoA ReductasesIschemic StrokePolymorphism, Single NucleotideProprotein Convertase 9AgedFemaleHumansMaleMiddle AgedHypolipidemic AgentsPharmacogenomic VariantsRisk AssessmentRisk Factors

Stichwörter der Autor:innen

genetic risk scoreischemic strokelipid‐lowering drug targetsprognosticssingle‐nucleotide polymorphisms

Substanzen

CETP protein, humanCholesterol Ester Transfer ProteinsHMGCR protein, humanHydroxymethylglutaryl CoA ReductasesHypolipidemic AgentsPCSK9 protein, humanProprotein Convertase 9

Autor:innen und Institutionen

  • Department of Epidemiology School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-communicable Diseases Suzhou Medical College of Soochow University Suzhou Chin…
  • Department of Epidemiology Tulane University School of Public Health and Tropical Medicine New Orleans LA.
  • Department of Cardiology The First Affiliated Hospital of Soochow University Suzhou China.
  • Department of Medicine Tulane University School of Medicine New Orleans LA.

ORCID-Profile: Qilu Zhang, Yang Liu, Zhengbao Zhu, Jing Zhang, Hao Peng, Jing Chen, Tan Xu, Yonghong Zhang, Jiang He

Zitieren

APA

Sun, L., Zhang, Q., Shi, M., Liu, Y., Zhu, Z., Zhang, J., Peng, H., Wang, A., Chen, J., Xu, T., Zhang, Y., & He, J. (2024). Associations Between Gene Variants of Lipid‐Lowering Drug Targets and Adverse Outcomes After Ischemic Stroke. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.036544

Vancouver

Sun L, Zhang Q, Shi M, Liu Y, Zhu Z, Zhang J, et al. Associations Between Gene Variants of Lipid‐Lowering Drug Targets and Adverse Outcomes After Ischemic Stroke. Journal of the American Heart Association. 2024. doi:10.1161/jaha.124.036544

BibTeX
@article{Sun2024,
  author = {Sun, Lulu and Zhang, Qilu and Shi, Mengyao and Liu, Yang and Zhu, Zhengbao and Zhang, Jing and Peng, Hao and Wang, Aili and Chen, Jing and Xu, Tan and Zhang, Yonghong and He, Jiang},
  title = {Associations Between Gene Variants of Lipid‐Lowering Drug Targets and Adverse Outcomes After Ischemic Stroke},
  journal = {Journal of the American Heart Association},
  year = {2024},
  doi = {10.1161/jaha.124.036544}
}
Kostenlos starten →